Lung Cancer

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses liquid biopsies in lung cancer.

The FDA has approved a supplemental new drug application for the use of 180-mg tablets of brigatinib for the treatment of patients with non–small cell lung cancer.

Suresh A. Ramalingam, MD, discusses the practice-changing FLAURA findings and his thoughts on sequencing should the FDA approve osimertinib in the frontline setting of non-small cell lung cancer.

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.

Recent approval of immunotherapy in the first-line setting for treatment of patients with locally advanced and metastatic non–small cell lung cancer without driver mutations represents changes in care.

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the emerging agent lurbinectedin in the small cell lung cancer (SCLC) landscape.